1. Home
  2. GANX vs ICCM Comparison

GANX vs ICCM Comparison

Compare GANX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • ICCM
  • Stock Information
  • Founded
  • GANX 2017
  • ICCM 2006
  • Country
  • GANX United States
  • ICCM Israel
  • Employees
  • GANX N/A
  • ICCM N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • ICCM
  • Sector
  • GANX Health Care
  • ICCM
  • Exchange
  • GANX Nasdaq
  • ICCM Nasdaq
  • Market Cap
  • GANX 69.0M
  • ICCM 61.1M
  • IPO Year
  • GANX 2021
  • ICCM N/A
  • Fundamental
  • Price
  • GANX $1.58
  • ICCM $1.02
  • Analyst Decision
  • GANX Strong Buy
  • ICCM Strong Buy
  • Analyst Count
  • GANX 5
  • ICCM 1
  • Target Price
  • GANX $8.20
  • ICCM $2.00
  • AVG Volume (30 Days)
  • GANX 526.2K
  • ICCM 2.2M
  • Earning Date
  • GANX 11-13-2025
  • ICCM 08-13-2025
  • Dividend Yield
  • GANX N/A
  • ICCM N/A
  • EPS Growth
  • GANX N/A
  • ICCM N/A
  • EPS
  • GANX N/A
  • ICCM N/A
  • Revenue
  • GANX N/A
  • ICCM $2,787,000.00
  • Revenue This Year
  • GANX N/A
  • ICCM $3.95
  • Revenue Next Year
  • GANX N/A
  • ICCM $266.15
  • P/E Ratio
  • GANX N/A
  • ICCM N/A
  • Revenue Growth
  • GANX N/A
  • ICCM N/A
  • 52 Week Low
  • GANX $1.36
  • ICCM $0.48
  • 52 Week High
  • GANX $3.19
  • ICCM $1.66
  • Technical
  • Relative Strength Index (RSI)
  • GANX 39.85
  • ICCM 51.92
  • Support Level
  • GANX $1.55
  • ICCM $0.98
  • Resistance Level
  • GANX $1.78
  • ICCM $1.11
  • Average True Range (ATR)
  • GANX 0.13
  • ICCM 0.06
  • MACD
  • GANX -0.03
  • ICCM -0.00
  • Stochastic Oscillator
  • GANX 6.00
  • ICCM 12.12

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: